{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031441","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.871183+00:00","generated_at":"2026-06-04T19:03:58.602629+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma reports FY2023 cash $101.7M; Phase 3 sarcoidosis study enrollment to complete Q2 2024","bullets":["Cash, equivalents, restricted cash, investments at Dec 31, 2023: $101.7M; cash runway through BLA filing.","Phase 3 EFZO-FIT study in pulmonary sarcoidosis enrollment expected to complete Q2 2024; DSMB allowed unmodified continuation.","Launched Individual Patient Expanded Access Program for patients completing EFZO-FIT study.","Phase 2 EFZO-CONNECT study in SSc-ILD enrolling (proof-of-concept, up to 25 patients); multiple U.S. sites open.","R&D expenses $42.3M, G&A $13.0M for year 2023; no product revenue as clinical-stage biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031441","json":"https://secwatch.observer/filing/0000950170-24-031441.json","markdown":"https://secwatch.observer/filing/0000950170-24-031441.md","text":"https://secwatch.observer/filing/0000950170-24-031441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/life-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:03:58.602629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3758e9e455bbef2ac205727a819838e8a2050d8f","claim":"aTYR PHARMA INC updated its the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"51dc9a3a31c8e8fd963b7ec0756864dd45c0123a","claim":"aTYR PHARMA INC updated its the fourth quarter ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}